Skip to main content
. 2021 Feb 2;45(4):12. doi: 10.3892/or.2021.7963

Figure 2.

Figure 2.

Exosomal miR-663b promotes the metastasis of cervical cancer cells. (A) HeLa cell migration with normal or TGF-β1-treated exosomes was assessed by wound healing assay. (B) CaSki cell migration with normal or TGF-β1 treated exosomes was assessed by wound healing assay. (C) Migration and invasion abilities of HeLa cells with normal or TGF-β1-treated exosomes were detected by Transwell assays. (D) Migration and invasion abilities of CaSki cells with normal or TGF-β1-treated exosomes were detected by Transwell assays. (E) Schematic diagram of the exosomes-tumor cell experiments. (F and G) miR-663b expression levels in HeLa and CaSki cell-secreted exosomes from the Exo-miR-663b and Exo-miR-663b-KD group were analyzed by qPCR. (H) Wound healing assays were used to detect HeLa cell migration after treatment with exosome from miR-663b-KD or WT cells upon TGF-β1 exposure. (I) Wound healing assays were used to detect CaSki cell migration after treament with exosome that from miR-663b-KD or WT cells upon TGF-β1 exposure. (J) Transwell assay was performed to assess the effect of miR-663b-KD or WT exosomes following exposure of TGF-β1 on migration and invasion of HeLa cells. (K) Transwell assay was performed to measure the effect of miR-663b-KD or WT exosomes following exposure of TGF-β1 on migration and invasion of CaSki cells. Magnification, ×100, *P<0.05, **P<0.01, ***P<0.001. Exo-miR-663b, exosomes from the TGF-β1 treatment group; Exo-NC, exosomes from the negative control group; Exo-miR-663b-KD, exosomes from the miR-663b-knockdown group. TGF-β1, transforming growth factor-β1; MGAT3, mannoside acetylglucosaminyltransferase 3; WT, wild-type.